Status
Conditions
Treatments
About
We aim to retrieve olfactory bulbs (OBs) from suitable human donors. We have defined two groups who will qualify:
Group 1 - Deceased Donors:
1A: Donors after brainstem death (DBDs) undergoing solid organ donation
1B: Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
Group 2 - Living Donors:
Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
We aim to optimise OB collection and Olfactory Ensheathing Cell (OEC) culture and storage. We will study the effects of patient diagnosis, age, cause of death (if applicable), co-morbidities and warm ischaemic time on cell survival and regenerative function.
In future studies we aim to store OECs in a GMP facility and transplant OECs into patients with spinal cord injuries.
Full description
Spinal cord injury (SCI) is a devastating condition. To date there is no treatment to improve outcome. There is limited regenerative capacity of the central nervous system (CNS), such that damaged neurons and severed axons are not replaced.
A substantial body of evidence suggests that olfactory ensheathing cells (OECs) obtained from olfactory bulbs (OBs) facilitate neuronal regeneration in rodents and humans with SCI. Indeed, transplanting autologous OECs from an OB into the injury site improved neurological outcome in a patient with SCI.
Harvesting autologous OBs to culture OECs has several disadvantages:
Investigators will collect human OECs from suitable donors which we have defined as two groups. Group 1 patients will be brain dead donors identified by the neuro-intensive care team as potential candidates for solid organ donation. The OBs will be retrieved as near to death as possible. Group 2 patients will be living donors undergoing elective neurosurgery in which the olfactory nerve is sacrificed as part of that procedure.
There are two OBs located at the anterior skull base, responsible for transmitting the sensation of smell from the nose to the brain. Obtaining OECs requires a craniotomy (opening the skull) to remove the OBs.
PHASE 1 will be divided into 2 stages. In stage 1 we will culture OECs and characterise them in the central laboratory. We aim to determine how the yield of OECs and their regenerative properties are affected by freeze-thaw, time left at room temperature and time left at 40C before culture as well as patient age. Each harvested sample will be transferred to the lab for further processing. Processing includes but is not limited to histological fixation, sectioning and staining, cell culture and storage. Some OECs will be frozen in liquid nitrogen to determine whether they can indeed be stored. In stage 2 we will transfer OECs outside St. George's to a GMP facility (to be determined). In the GMP facility, the OECs will be processed and stored according to the optimised conditions we have determined.
In PHASE 2, the OECs will be transplanted into patients with SCI.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Group 1 - Deceased Donors 1A
1B
Group 2 - Living Donors
Exclusion criteria
And applicable to group 2 only:
Patients unable to consent for surgery
50 participants in 3 patient groups
Loading...
Central trial contact
Florence Hogg, MBChB; Marios Papadopoulos, FRCS (SN)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal